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Adjuvant chemotherapy in breast cancer patients post resection has been estimated to reduce 
mortality rates by up to 30%.  However, the heterogeneous nature of the disease and patients 
implies that not all patients should receive the treatment.   Many existing prognostic tools, may not 
definitively estimate the most effective treatment strategy, resulting in an indeterminate risk 
classification.  In such cases gene expression profiling tests can aid the treatment decision.   
Methods 
This study evaluated the cost-effectiveness of EndoPredict in patients with indeterminate risk 
classification.  A mathematical model was constructed to determine how the change in treatment 
decisions impacted the long term health of the population, and the future cost implications to the 
NHS. 
Results 
EndoPredict was found to lead to 36.9% of patients having a change in treatment decision.  As a 
result its use was found to result in an increase in population health but also in total costs, resulting 
in an incremental cost-effectiveness ratio of £26,836 per quality adjusted life year.  This was subject 
to significant parametric and structural uncertainty.  
Conclusion 
While EndoPredict was found to be more expensive overall, its ability to affect a more optimal 
allocation of chemotherapy, resulted in long term health gains, however, they were insufficient to 







Breast cancer is one of the most common types of cancer in women. In the UK 30% of all cancer 
patients and about 42,489 female patients are diagnosed with breast cancer every year.[1] In early-
stage breast cancer, patients undergo surgery (mastectomy or lumpectomy) to remove the primary 
cancer. However, there is a risk that some cells may have left the primary tumour before removal 
and spread to other parts of the body as micro- metastases.  The risk of metastatic disease, and 
death from breast cancer can be reduced with systemic adjuvant therapy.  The majority of breast 
cancers are hormone sensitive (oestrogen receptor (ER) +ve) and there will be clear benefit from 
tablet based anti-hormonal treatment such as tamoxifen or an aromatase inhibitor.  Furthermore, 
systemic anti-cancer chemotherapy can be added to the treatment regimen to attempt to directly 
target residual microscopic metastases and lower the risk of the cancer returning. According to the 
Early Breast Cancer Trialists’ Collaborative Group (EBCTCG), post-operative chemotherapy can 
reduce mortality rates by approximately 30% in ER +ve patients.[2]  
Despite the strong evidence of a reduced risk of disease recurrence with chemotherapy treatment, 
the heterogeneous nature of both the disease and the patients treated requires the consideration of 
the patient specific risk of recurrence of the cancer. Patients at high risk of recurrence would be 
expected to benefit significantly from chemotherapy, while those at low risk unlikely to benefit.  This 
study focuses on the patients whose risk falls between the clearly high and low risk patients, those 
deemed of intermediate risk of recurrence using conventional risk estimation approaches, and thus 
in whom the decision to provide chemotherapy or not is most challenging.  
Tools with which to estimate the risk profile of future disease recurrence can be broadly categorised 
as gene and non-gene informed prognostic tools, where examples of gene informed tools include 
Oncotype DX and EndoPredict and non-gene informed the Nottingham Prognostic Index [NPI], and 
PREDICT.  Recent NICE guidance[3] considered the use of gene expression profiling alongside 
conventional risk tools, recommending the use of Oncotype DX in patients assessed as being at 
intermediate risk by non-gene informed tools, but recommending against the other gene informed 
tools assessed (MammaPrint, IHC4 and Mammostrat).  The subsequent entry to market of 
EndoPredict and Prosigna resulted in NICE issuing a Medtech Innovation Briefings (MIB44 and MIB27 
both in 2015),[4, 5] a means by which NICE provide guidance on the new technologies but not a 
robust recommendation.   As such, EndoPredict has currently no formal NICE recommendation 
status, and as the Briefing demonstrated, only limited clinical or economic evidence.  An updated 
NICE Guidance is currently being produced.[6]  
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In this manuscript we present the findings of an economic analysis of a trial into the use of 
EndoPredict, through this we hope to aid decision making of patients with an initial intermediate risk 
score using standard risk tools, considering both the potential for short term cost saving and long 




Details of the trial on which this analysis is based are provided elsewhere[7] but in brief, it is a small 
scale (n=149 patients), manufacturer sponsored (an unrestricted educational grant from Myriad 
Genetics) study of EndoPredict, a validated multigene test which provides additional prognostic 
information to the risk of distant recurrence of breast cancer patients, independent of clinic-
pathologic parameters[8]. The EndoPredict score is combined with two clinical parameters, nodal 
status and tumour size, resulting in a hybrid molecular-clinico-pathologic prognostic score (EPclin), 
we will use the term EndoPredict to reflect the use of the initial score and clinical parameters.[9, 10]  
The trial was conducted across eight sites in the south-east of England.  Between July 2015 and 
September 2016 women at each site were eligible for inclusion if they were the first presentation of 
early breast cancer with all known disease surgically removed, Oestrogen Receptor +ve and HER-2 
negative, with no clear decision on whether chemotherapy should be given as adjunct based on 
current prognostic criteria as preferred by the clinical team (e.g. an intermediate Nottingham 
Prognostic Index risk/PREDICT benefit).   The mean age of patients was 56.5, with a range of 25.9 to 
77.2.  Of the 149, 19 (13%) were diagnosed with Grade I, 87 (57%) Grade II, and 43 (29%) Grade III 
cancer.  Both nodal positive (n=141) and negative (n=8) patients were included, a histogram of the 
number of nodes involved in included in the supplementary appendix.   
With their oncologist, patients identified as being in the intermediate risk group came to a 
provisional treatment decision regarding the use of chemotherapy, and if so relevant regimen, dose 
and cycle length, using standard clinical-pathological criteria constituting the standard practice of 
the oncologist.  This could include the use of online prognostic tools including PREDICT and 
Adjuvant! Online (which was offline for most of the trial period).  This decision was recorded prior to 
patients being consented for the trial.  If the patients consented a tissue sample was sent for 
EndoPredict testing prior to re-consultation within two weeks, at which point the results were 
discussed and an updated treatment regimen decided.  No trial follow up was planned beyond the 
second consultation, as such the primary outcome is the impact of EndoPredict to change the initial 




This economic analysis consists of a two-step evaluation.  First, we investigate whether the addition 
of EndoPredict increases or decreases the use and intensity of chemotherapy in the trial population, 
and the associated direct cost implications to the NHS.  Secondly, in order to conceptualise the 
potential long-term cost and health related implications of the test, a mathematical model is 
constructed.  The analysis takes the perspective of the NHS, such that only the costs directly incurred 
by the NHS are included.  The primary outcome of interest in patient health, estimated through 
quality adjusted life years (QALYs).  QALYs are discounted at a rate of 3.5% per annum, consistent 
with standard methods.[11] 
Cost are measured in 2016 Pound Sterling, and future costs and benefits are discounted at a rate of 
3.5% per annum.  Where costs are drawn from sources before 2016 they are inflated using the 
Hospital and Community Health Services (HCHS) index.[12]  Where available evidence from the trial 
was used to inform micro-costing analysis, for example with chemotherapy costs, if no such 
evidence was available evidence from the wider literature and reference cost resources were used.   
Uncertainty is conceptualised in the analyses through the use of probabilistic sensitivity analysis 
(PSA), conducted over 3,000 iterations.  The PSA analysis draws from informative distributions of all 
of the key model parameters, including the impact of the addition of EndoPredict to the treatment 
decision, the model transitions, costs, and patient related quality of life, the informative 
distributions are detailed in Table 1.   
The long term analysis results include estimates of the incremental costs, QALYs, and net monetary 
benefit (NMB), in addition to the results of the PSA, estimating the probability of EndoPredict being 
a cost-effective intervention relative to standard decision criteria only.  Value of information analysis 
is conducted to estimate the consequences of an incorrect decision.  Additionally, a scenario analysis 
is conducted to explore the potential impact of the proportion of patients who receive treatment 
that deviates from the EndoPredict risk score, for example a patient who has an EPclin high score 
reported but did not received chemotherapy.  
 
Chemotherapy cost analysis 
This analysis considers both the proportion of patients receiving chemotherapy with and without 
EndoPredict as well as the intensity and type of chemotherapy prescribed.  The analysis considers 
the direct costs to the NHS of the treatment regimens to determine the impact of EndoPredict on 
the cost of chemotherapy treatment, using an intention to treat approach.  Due to the lack of 
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patient follow up in the trial only the acquisition and provision of the prescribed treatments, and the 
cost of EndoPredict are estimated, the subsequent cost implications of adverse events and increased 
care are incorporated in the long term extension detailed in the next section.  The cost of each 
regimen is estimated at a patient level from the trial data, both before and after the EndoPredict 
decision, which are used to represent two arms of the decision problem.  For the cost analysis details 
on the selected regimen, dose, number of cycles, and body surface area (estimated using the 
Mosteller formula) are combined with the unit cost of each regimen, drawn from the British National 
Formulary (BNF)[13] and the estimated laboratory and human resource costs of delivery, applied as 
a fixed cost per cycle of £139.39.[14]  To reduce the impact of intra-site variation regimen dose was 
standardised to the lead site’s approach, the analysis takes the lowest cost of each chemotherapy 
drug from the BNF, assuming perfect divisibility of vials with no waste.  Only the costs of 
chemotherapy treatment is included in the analysis due to the low cost and high degree of variation 
in reporting of endocrine therapies in the trial.   
To consider the full short term cost of the use of EndoPredict its cost is also factored in to this 
analysis.  The cost of EndoPredict is drawn from the NICE briefing[4] which reported a cost of £1,500. 
After standardisation and cleaning of the trial data three cases of missing drug dose were detected, 
these were imputed using the mean dose of other patients receiving that drug.  Three cases of 
missing height and weight were detected (required for body surface area), which were imputed as 
an unadjusted average from the rest of the trial patients.  Two patients were detected as having a 
decision of chemotherapy but with no named drugs in the regimen, these patients had the average 
cost across matched treatment decisions imputed.  Finally, two patients who were enrolled in the 
trial but did not have EndoPredict conducted were dropped from the analysis, leaving 149 patients.   
The long term mathematical model 
As part of this analysis a systematic search of the literature was conducted, the search strategy for 
which is provided in the Supplementary Appendix.  It found no existing evaluative models suited to 
the required long term analysis, with the only previous economic analysis of EndoPredict that by 
Blank in 2014.[9]  While the Blank study is informative, and is used to guide several of the model 
parameter values, as it was conducted from a German perspective without focus on the 
intermediate risk group, it was not considered directly comparable with this analysis.  This 
conclusion is consistent with the review of the literature conducted by NICE for the EndoPredict 
Briefing.[4]  As a result, a de novo mathematical model was constructed with which to compare the 
long-term costs and benefits associated with a cohort of patients assessed using standard decision 
criteria of the treating oncologist, compared to standard decision criteria  plus EndoPredict.   
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The model represents a decision tree leading to a three state Markov cohort analysis with a lifetime 
timeframe and an annual cycle length.  The Markov model includes three disease states modelled 
(disease-free, recurrent disease, and death), and the decision tree divides patients into one of four 
groups determined by their EndoPredict risk categorisation and treatment decision: EPclin low + 
chemotherapy, EPclin low + no chemotherapy, EPclin high + chemotherapy, and EP clin high + no 
chemotherapy.  The modelled base-case population selected was done so to matches the average 
patient from the trial which we believe reflects the real world population well in this setting, being a 
cohort of 56 year old women who were diagnosed with oestrogen receptor-positive, human 
epidermal growth factor receptor 2 negative (ER+/HER2-) early breast cancer, having had an 
intermediate risk score using the standard risk tool.  The model structure is presented in Figure 1.    
[Figure 1 here] 
 
Parameter Values 
EndoPredict and treatment classification 
As presented in the model schematic (Figure 1), the population is divided into four risk and 
treatment populations for both the arm that had access to EndoPredict or used a standard decision 
making process only.  The chemotherapy decisions made in the ‘No EndoPredict’ arm is informed by 
the decisions made by the clinician and patient prior to the use of EndoPredict in the trial, and as 
such is assumed to represent the treatment decision that would result from the standard decision 
making process indicative of current NHS practice.  Similarly, the chemotherapy decisions 
represented in the ‘EndoPredict’ arm of the model are the updated decisions made in the trial after 
the estimation of the EndoPredict risk score.  The proportion of patients in each of the four 
populations is estimated directly from the trial results, reported in Table 1.   
Transition probabilities 
Prior to entering the Markov part of the model, all patients on a chemotherapy regimen have the 
potential of dying due to related toxicity.  This probability is estimated from a study by Campbell.[15] 
The Markov model’s three state structure allows patients to transition from each state to any which 
represents a worsening health state (i.e. disease free to metastases, disease free to death, 
metastases to death).   
The EPclin score and treatment decision associated with a patient is assumed to only effect the 
transition probabilities from the initial disease free state to metastases.  Both factors are considered 
as independent factors affecting the expected probability of a patient experiencing disease 
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metastases, the estimates and sources of these effects are shown in Table 1.  The annual probability 
of metastases for the 10 years after surgery for patients receiving no chemotherapy is estimated 
from the study by Blank,[9] stratified by EPclin score.  The published Kaplan-Meier curves for 
metastatic free survival were digitised (using Engauge[16]) and an exponential hazard function fitted 
(chosen due to the findings of Blank that this functions provide the best fit to the data).  The 
progression free survival curves were then adjusted by the mortality rate of the population to yield 
the required metastases rate, associated standard errors were estimated to inform the PSA analysis.   
For the patients who receive chemotherapy a treatment effect is applied to the disease free to 
progressed transition probability.  Consistent with Blank[9] a treatment effect of 0.69 (SE 0.04) is 
used which is independent of the risk status of the patients. 
10 years after surgery all patients still in the disease free state are assumed to be ‘cured’ of the 
original disease due to the inability of our model to differentiate cancers which occur after this time 
point with the initially treated cancer rather than a newly occurring one, and as such are no longer 
able to transit to a state of disease metastases, only to death from unrelated causes.  The impact of 
this assumption is expected to be minimal as the death from ‘unrelated causes’ will include potential 
long term recurrences.  
The transition probabilities governing mortality, from the disease free and progressed states were 
informed by two sources.  Death not related to breast cancer in both the disease free and 
progressed states was assumed to occur at a rate consistent with the age and gender adjusted rate 
of the wider population, informed by the ONS’s estimates of mortality, which are adjusted to 
exclude deaths due to breast cancer. [17, 18]  An estimate of median life expectancy following 
disease recurrence is extracted from the study by Chang[19] and re-estimated as a fixed annual 
probability to inform post metastases mortality, the lower and upper confidence interval from Chang 
were used to estimate the SE to inform the PSA. 
Health related quality of life (HRQoL) outcomes 
Estimates to inform the HRQoL of all states in the model are estimated through the combination of 
two sources.  Estimates of the HRQoL of ‘cured’ patients (i.e. those who had been disease free for 10 
years after surgery) are informed by age and gender adjusted population norms.[20]  All other states 
in the Markov model draw from the study by Lidgren,[21] which estimates HRQoL scores in different 
states of breast cancer using the EQ-5D-3L measure.  All HRQoL values were defined as gamma 
distributions for the PSA.[22] 
Non Drug Acquisition Costs 
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In addition to the short term costs drawn directly from the chemotherapy cost analysis, two further 
categories of costs are considered: the chemotherapy related adverse events, and the long term 
costs associated with each of the Markov states.  All parameter estimates are presented in Table 1. 
The cost of chemotherapy related adverse events are estimated from Paulden (subject to 2012 
exchange rate from Canadian dollars as well as inflation),[14] incorporating the cost of treating 11 
common adverse events.  Paulden is additionally the source of the cost of fatal chemotherapy 
toxicity.  All adverse events are assumed to occur within the first year after treatment.  The SEs 
required to inform the PSA are not reported in Paulden for the adverse event and toxicity costs, as a 
result the assumption is made that the proportional relationship between the mean and SE observed 
in the long term costs (presented in the next paragraph) is the same as for these short term costs (a 
proportion of 0.25). 
The long term costs associated with membership of the different states modelled is informed by two 
sources.  The cost to the NHS of providing care for disease free patients reflects the 
recommendations of NICE that patients should be followed up with annual mammographies,[23] 
coupled with the argument made by Campbell that disease free patient would be expected to attend 
two oncology clinics a year.[15]  The cost of caring for disease free patients is assumed to be fixed. 
All other long term costs are informed by the study by Karnon,[24] which estimated the healthcare 
costs for the treatment of breast cancer recurrent events.  Estimated costs for local, contralateral, 
and distant recurrence are weighted by their incidence in the Karnon study to estimate a weighted 
average annual cost for recurrence.  To reflect the high initial costs of responding to disease 
metastases, the model discriminates between the costs to the NHS in the first year post metastases, 
and all subsequent years.  The Karnon study is additionally used to inform the cost of terminal care. 
[Table 1 here] 
Results 
Chemotherapy cost analysis 
The short term costs associated with the two arms of the analysis are presented in Table 2, broken 
down into the acquisition and provision of chemotherapy alone and the impact of additionally 
incorporating the cost of EndoPredict.  Further details of the treatment regiments recommended at 
each stage of the decision and the costing approach are provided in the Supplementary Appendix. 
The results show that EndoPredict led to a small but not statistically significant increase in the mean 
per patient cost of acquisition and provision of chemotherapy to the NHS (£149, p=0.4366).  This 
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increase resulted from an insignificant decrease in the cost per cycle (£1 less for the EndoPredict 
arm, £982 compared to £983) but an increase in the number of cycles prescribed (0.15 cycles more 
with EndoPredict, 4.52 compared to 4.68).   
Despite the number of patients receiving chemotherapy in the two arms of the analysis being similar 
(61 for standard decision criterial only and 62 for EndoPredict plus standard criteria) the mix of 
patients is very different.  28 patients who, using standard criteria only, would have had no 
chemotherapy had their treatment plan changed to receive chemotherapy with EndoPredict, 
similarly 27 patients had their treatment changed from chemotherapy to no chemotherapy. 
Table 2 additionally shows that when the cost of providing EndoPredict to all 149 patients, is 
included in the analysis, the expected cost difference becomes statistically significant (£1,593, 
p=0.0004). 
[Table 2 here] 
Cost-effectiveness Analysis 
The probabilistic results of the long term cost-effectiveness analysis are presented in Table 3.  They  
show that the use of EndoPredict to inform clinical decision making is expected to be associated with 
higher average discounted costs (£1,482 more), more life-years (0.13) and more QALYs (0.06).  As a 
result the base case analysis suggests that, at a cost-effectiveness threshold of £20,000 per QALY, 
the use of EndoPredict is not cost effective, with an incremental cost-effectiveness ratio (ICER) of 
£26,836/QALY.   
[Table 3 here] 
The implications of the use of EndoPredict over time can be conceptualised by plotting the 
incremental cumulative net monetary benefit (NMB), as shown in Figure 2.  The NMB is a combined 
measure of the incremental cost and QALYs associated with an intervention, estimated using the 
formula: 
NMB = (QALYs x cost-effectiveness threshold) – costs 
Further details regarding the use and interpretation of the incremental cumulative NMB curve are 
published elsewhere.[25]  The figure shows that the initially high incremental cost associated with 
EndoPredict, due to both the cost of the test and additional chemotherapy, is slowly recouped as the 
long term health benefits that result from the improved decision making are realised.  The figure 
shows that, assuming a cost-effectiveness threshold of £20,000/QALY, the incremental NMB never 
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become positive.  However, with a threshold of £30,000/QALY after 27 years sufficient benefits have 
been recouped to make the use of EndoPredict cost-effective given the base-case assumptions. 
[Figure 2 here] 
The uncertainty around the base-case result can be characterised through the PSA, which allows for 
the estimation of the probability that each decision is cost-effective at different thresholds, and thus 
test the parametric uncertainty.  This is achieved through the combination of the estimated point 
probabilities in Table 3, the ‘cloud’ of PSA iteration results in Figure 3, and the cost-acceptability 
curves in Figure 4.  These show that the high level of uncertainty in several parameters permeates 
into the final result, and that while in only a very small number of iterations (0.07%) EndoPredict was 
found to dominate the standard tool arm, such that it was both cheaper and more effective at a 
threshold of £20,000/QALY, it was associated with the larger probability of being cost effective 
(39.6%).  A small proportion of iterations resulted in EndoPredict being associated with fewer QALYs 
(16%). 
[Figures 3 and 4 here] 
Furthermore, it is possible to quantify the scale of the likely consequences of an incorrect decision 
through the use of value of information methodology,[22] which combines the likelihood of an 
incorrect decision at given cost-effectiveness threshold, the cost and QALY consequences if the 
decision in wrong, and the size of the population expected to be treated.  An estimate of the 
effective population was estimated using incidence data from CRUK[26] and Macmillan,[27] along 
with an estimate of the proportion of patients who would receive an intermediate risk score using 
standard citeria from Paulden,[14] and thus be eligible for use of EndoPredict, giving a per annum 
incident population of 7,114.  Coupled with the assumption of a 10 year technology horizon the 
model estimates the consequence of decision uncertainty at a threshold of £20,000/QALY to be 
£23.4m (equivalent to 1,171 QALYs).  
A number of one way sensitivity analyses were also conducted, adjusting the key parameters by 
±20% to explore the impact on the ICER.  The results are produced in a tornado diagram in the 
Supplementary Appendix, showing that the result was found to be sensitive to changes in the 
progression rate, age and the discount rate as was expected a priori.  However, these scenarios are 
purely illustrative as the changes are arbitrary, but reflect the areas of key sensitivity in the model.  
Test of the ‘deviation factor’ 
One of the strengths of this analysis and the trial on which it is based is the incorporation of the 
reality that even if an EndoPredict test is conducted patients (and their doctors) may still decide 
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against the treatment decision recommended by EndoPredict.  This can be seen in Table 1 where 
despite 17 patients (23% of the EPclin high patients) having a high EPclin score they chose to not 
have any chemotherapy, and 5 (7% of the EPclin low patients) with a low EPclin score chose to have 
chemotherapy.  These events are referred to here as the ‘deviation factor’, and the scale of 
deviation that might cause EndoPredict to no longer be cost-effective can be tested in the 
mathematical model through one and two way scenario analysis.  Using a threshold analysis we can 
estimate the level of ‘deviation’, or compliance of the final treatment choice with the recommended 
clinical guidance, at which the results of this cost-effectiveness analysis would be different. 
At a cost-effectiveness threshold of £20,000/QALY, as used in the base-case analysis, no level of 
deviation from the EndoPredict treatment recommendation was found to change the result that the 
use of EndoPredict is not cost-effective. 
However, at a threshold of £30,000/QALY, where EndoPredict would be cost-effective a one way 
sensitivity analysis suggests that if the proportion of EPclin high patients deviating from the 
recommended treatment reaches 34% OR the proportion of EPclin low reaches 10% (assuming the 
other remains as the base case rate) EndoPredict would no longer be cost-effective at a threshold of 
£30,000/QALY.  A two way analysis, maintaining the proportional relationship between the two 
deviation rates suggests that if the proportion of EPclin high deviating reached 29% AND the EPclin 
low reached 8% EndoPredict would no longer be cost-effective.  A simpler way to report the results 
of this analysis is that if the total proportion of patients deviating from the recommended treatment 
rose by 25% from those seen in the trial, given the assumptions of the base case analysis, 
EndoPredict would no longer be cost effective.   
Discussion 
This analysis of the EndoPredict trial found that the use of EndoPredict to aid chemotherapy decision 
making for patients with an initial intermediate risk score using standard decision criteria is not 
expected to be cost-effective compared to no additional decision tool at a cost effectiveness 
threshold of £20,000/QALY.  However, with an ICER of £26,836/QALY it would be considered cost-
effective at the upper bound of the NICE cost-effectiveness threshold, and as such falls within the 
grey area created by NICE’s soft threshold where consideration of broader factors including decision 
uncertainty is vital.   
The evaluation demonstrated that while EndoPredict was more expensive in the short term, due to 
both the upfront cost of the test and increased chemotherapy costs, the ability of the test to affect a 
more optimal allocation of chemotherapy, with 55 of 149 patients having a change of treatment 
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decision, resulted in long term health gains.  However, while the base-case analysis results in an ICER 
under the upper £30,000/QALY threshold conventionally used[11] the small scale and lack of follow 
up of the informative trial resulted in a large level of uncertainty around this conclusion, shown by 
the high level of decision uncertainty (39.6% at £20,000/QALY).  As a result the consequence of 
decision uncertainty, an estimate of the population health implications should the findings of this 
analysis be found to be incorrect as further evidence emerges, are high (estimated at £23.4m, 
equivalent to 1,171 QALYs). While recognised to be hard to set against a reference standard,[28] 
these findings demonstrate the importance of further research in this area, whether or not 
EndoPredict is recommended for routine use in the NHS in this population. 
In addition to the evaluation’s robust quantification of the intrinsic uncertainty of the decision, it is 
strengthened by its ability to capture and reflect the frequency with which the treatment decision 
deviated from the recommended action estimated from EndoPredict.  Such factors are highly 
relevant in real world clinical application, as the final, patient based, treatment decision is likely to 
take into account factors beyond simple clinical and cost-effectiveness, and thus must be reflected.  
The available evidence has, however, led to a number of weaknesses of the analysis.  Primarily, the 
failure of the model to reflect the range of comparators to EndoPredict detailed in the recent NICE 
Guidance and Medtech Innovation Briefings.[3-5]  Attempts were made to identify relevant evidence 
with which to synthesise the findings of the EndoPredict trial, however, no studies were found 
relevant to the decision problem and the population.  While the NICE Guidance[3] reports some 
elements of their evaluation of some EndoPredict comparators (primarily Oncotype DX and ICH4), 
the lack of sufficient detail with which to compare their analytical approach with that presented 
here, makes any direct comparison potentially misleading, demonstrated by the significant 
difference in the mean lifetime cost and QALY of a patents on current practice across the two 
studies.  However, it is believed that current NHS standard practice remains the use of non-gene 
informed prognostic tools, and as such the failure of this analysis to incorporate comparators 
remains relevant to the current decision problem.  Our analysis is focussed on the NHS due to the 
setting of the trial and availability of relevant evidence, however, we believe our findings are 
applicable to other economies with developed healthcare services.  However, some international 
health technology agencies have different approaches to defining an appropriate cost-effectiveness 
threshold, as a result while the core findings may apply the decision maker’s conclusion regarding 
cost-effectiveness may differ.  
Other weaknesses include the presentation of the EPclin categorisation of patients as a binary high 
or low risk, while this is representative of its current use, ideally an analysis would be conducted that 
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reflected its continuous nature, determining the most cost-effective threshold for the provision of 
chemotherapy.  Similarly, while the various forms of chemotherapy prescribed in the trial are 
incorporated into the costing, there was insufficient evidence available in the literature relating to 
comparative effectiveness to reflect the potential impact of these difference regimens on long-term 
health outcomes, necessitating a simple chemotherapy or no chemotherapy decision problem.  The 
use of a small, single armed trial to inform the clinical role of EndoPredict also risks introducing 
unobserved bias to the analysis which may not be fully incorporated in the sensitivity analyses 
conducted.   
Furthermore, the use of relatively old evidence to inform our analysis, including post-metastatic 
survival estimates from a 2003 potentially biases the results, in this case overestimating the benefits 
of early diagnosis.  The incorporation of newer analysis published since this analysis was conducted 
would be expected to increase the cost-effectiveness of EndopPredict as the importance of early 
diagnosis is reduced with increase effectiveness of treatment for metastatic cancer.[29, 30]   
Additionally, the use of standard treatment decision making by the treating oncologist and patient as 
one of the treatment arms risks introducing uncertainty as it was difficult within the scope of the 
trial to determine what factors were considered most important or the use of additional tools such 
as PREDICT and Adjuvant! Online.  However, this is considered to be indicative of current practice 
within the NHS. 
As with any analysis, especially those such as this which rely on relatively small trial evidence with 
short follow-up, assumptions are required to consider the long-term cost-effectiveness, such as 
assuming the consistency of the trial population with that studied in Blank et al. However, it is our 
view that given such decisions must be made by decision makers it is often necessary to make such 
assumptions in light of limited evidence.  Such results should be used to highlight areas of further 
research. 
By using a three state Markov model our analysis represents a simpler form than published 
elsewhere, for example by Hall et al.[31]  While the analysis presented here was conducted in 2015, 
prior to the publication of these more detailed analyses, and a more detailed natural history model 
may provide additional capacity to identify benefits and costs of treatments, we do not believe the 
use of a three state model can be definitively correlated with a bias when estimating the cost-
effectiveness of EndoPredict.   
While a number of studies have considered the role of gene informed prognostic tools for all 
Oestrogen Receptor +ve and HER-2 negative post-surgery breast cancer patients, only the NICE 
14 
 
Diagnostic Guidance[3] has considered in detail the subgroup relevant to this study, those who 
additionally have an intermediate risk of recurrence using a non-gene informed tool.  However, the 
NICE Guidance did not considered the use of EndoPredict due to its market release after the 
analysis.  As a result, this study represents the first of its kind and is expected to be highly 
informative to subsequent evaluations by NICE and other health technology assessment bodies.  
Finally, we reflect that tools such as EndoPredict and its competitors do not exist on a dichotomous 
scale but as continuous risk scores which are used by clinicians and decision makers to inform 
relatively binary treatment decisions.  Therefore, we believe that future research is need on the 
implications of the interpretation of the continuous risk scores on not only clinical outcomes but also 
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Table 1A: Details of the chemotherapy regimen recommended at first and second decision 
 First decision Second decision 




31 20.8 30 20.1 
epirubicin plus 
cyclophosphamide 










0 0.0 2 1.3 
Endocrine only 88 59.1 87 58.4 
FEC 8 5.4 9 6.0 
FEC-T 7 4.7 4 2.7 
Docetaxel plus 
cyclophosphamide 



















Total number of nodes
24 
 






Table 2A: Systematic search strategy used to identify relevant previous analyses 
Number of searches Location of key word Key word 
#1 MeSH descriptor breast cancer 
#2 MeSH descriptor breast cancer prognosis 
#3 MeSH descriptor breast tumours 
#4 MeSH descriptor breast tumors 
#5 MeSH descriptor estrogen receptor 
#6 MeSH descriptor oestrogen receptor 
#7 MeSH descriptor Endopredict 
#8 MeSH descriptor Oncotype Dx 
#9 Title/Abstract [Clinical validation] and 
[Endopredict] 
#10 MeSH descriptor GEICAM 9906 trial 
#11 MeSH descriptor ABCSG 8 trial  
#12 Title/Abstract [Endopredict] and[cost 
effectiveness] 
#13 Title/Abstract [Endopredict] and [economic 
analysis] 
#14 Title/Abstract [Endopredict] and [economic 
evaluation]     
#15 All Fields (Combined search) #1 or #2 or #3 or #4 or #5 or #6 
or #9 
#16 All Fields (Combined search) #1 or #2 or #3 or #4 or #5 or #6 
or #10 






discount rate (1.5%, 6%)
Change in ICER from base-case /QALY
decrease 20% increase 20%
25 
 
#17 All Fields (Combined search) #1 or #2 or #3 or #4 or #5 or #6 
or #11 
#18 MeSH descriptor [multigene prognostic tool] 
#19 MeSH descriptor [molecular predictor] 
#20 MeSH descriptor [prognostic classification] 
#21 MeSH descriptor [gene expression analysis] 







(multigene prognostic tool and 
cost effectiveness) or 
prognostic tool and economic 








(molecular predictor and cost 
effectiveness) or (molecular 
predictor and economic 
analysis) or (molecular 








(prognostic classification and 
cost effectiveness) or 
(prognostic classification and 
economic analysis) or 








(gene expression analysis and 
cost effectiveness) or (gene 
expression analysis and 
economic analysis) or (gene 








(21 gene RT-PCR assay and cost 
effectiveness) or (21 gene RT-
PCR assay and economic 
analysis) or (21 gene RT-PCR 
assay and economic 
evaluation) 
#28 All Fields (Combined search) #1 or #2 or #3 or #4 or #5 or #6 
and #20 
#29 All Fields (Combined search) #1 or #2 or #3 or #4 or #5 or #6 
and #21 
#30 All Fields (Combined search) #1 or #2 or #3 or #4 or #5 or #6 
and #22 
#31 All Fields (Combined search) #1 or #2 or #3 or #4 or #5 or #6 
and #23 
#32 All Fields (Combined search) #1 or #2 or #3 or #4 or #5 or #6 
and #24 
#33 Title/Abstract [distant recurrence] and [cost 
effectiveness] 




#35 All Fields (Combined search) #1 or #2 or #3 or #4 or #5 or #6 
or #30 
#36 All Fields (Combined search) #1 or #2 or #3 or #4 or #5 or #6 
or #31 
 
Table 1: Parameter estimates 



























































EPclin high no 
chemo 
42 (28.2%) 
EPclin low chemo 29 (19.5%) 




EPclin high chemo 57 (38.3%) 
EPclin high no 
chemo 
17 (11.4%) 
EPclin low chemo 5 (3.4%) 















Hazard ratio for risk of disease metastases 
for those on chemotherapy (normal) 
0.69 0.04 [8] 
Probability of chemo toxicity related 
mortality (beta) 
3.71 x10-3 Alpha – 28 
Beta - 7540 
[14] 
DF to recurrence, 0 
to 10 years, 
exponential shape 
estimate (normal)  
EPclin high 0.9996 1.43x10-5 [8] 
EPclin low 0.9984 3.07x10-5 
DF to recurrence, 10 years plus 0 N/A Assumption 
Recurrence to death (normal) 0.327 0.0263 [18] 
Utilities  Year 1 no chemo (gamma) 0.744 Alpha – 118 
Beta – 6.28 
x10-3 
[20] 
Year 1 chemo (gamma) 0.62 Alpha – 167 
Beta – 3.71 
x10-3 
Year 2-10 metastases-free (gamma) 0.779 Alpha – 2140 
Beta – 3.64 
x10-3 
Year 10+ no chemo (gamma) Age adjusted population 
norms 
[19] 
Recurrence no chemo (gamma) 0.648 Alpha – 102 





Recurrence chemo (gamma) 0.692 Alpha – 404 
Beta – 1.71 
x10-3 
Costs Cost of Endopredict (fixed price) £1,500 N/A [4]  
Chemo costs Acquisition costs 
and number of 
cycles 
Informed by trial analysis reported in Results 
Non-acquisition 
costs, per cycle 
(fixed) 
£139.39 N/A [13] 
Mean cost of 
treating chemo 
adverse events 
 £736.73 Alpha – 16.7 
Beta – 44.2 
[13] 
Cost of fatal chemo 
toxicity (gamma) 
 £22,485.20 Alpha – 16.7 
Beta – 1350 
[13] 
Cost of care 
disease free 
patients (fixed) 





[14, 22, 25] 
5+ years  £0 N/A 
Cost of care 
regressed patients 
(gamma) 
1st year post 
regression 
£13,329.16 Alpha – 177 
Beta – 75.4 
[23] 
2+ years £4,079.51 Alpha – 403 
Beta – 10.1 
Cost of terminal care for all patients 
except chemo toxicity (gamma) 
£4,491.99 Alpha – 79.0 
Beta – 56.9 
 
Table 2: Results of cost-minimisation analysis 
 Mean standard tools 
only cost (SD) 
Mean EndoPredict and 
standard tools decision 
cost (SD) 
Total cost difference 
(per patient average, p 
value that difference is 
significant) 
Cost of the acquisition and 
delivery of chemotherapy per 
treated patient 
£4,687 (5,074) over 61 
patients 




Total short term cost 
(chemotherapy costs plus cost of 
EndoPredict to all follow-up) 
£1,919 (3,972)  £3,512 (4,138)  +£237,357 (£1,593, 
p=0.0004) 
 













ICER (cost per 
QALY) 
Probability of being cost-










£8,710 26.70 12.70 £26,836/QALY 39.6% 52.4% 
 
 
